Posted inHematology-Oncology news
Discovery of a Novel B-ALL Subtype Defined by IGH::FENDRR Rearrangement and KRAS Mutations With Poor Chemotherapy Response
A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy and targeted interventions.